TUNIGHT + TUMORROW

For the maintenance treatment of COPD,
TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) significantly reduced exacerbations and improved lung function with an evening and morning dose1-5

TUDORZA® PRESSAIR® is not indicated for the initial treatment of acute episodes of bronchospasm (i.e. rescue therapy).1

Learn How It Works

Improved Lung Function*

Improved bronchodilation (forced expiratory volume in 1 second [FEV1]) with a dose in the morning and evening.1-4,6

Learn More

Reassuring Dual Feedback†

Provides visual cues (color-controlled window) and an audible click when patients inhale their dose correctly.

How To Use

Savings Program‡

Eligible commercially insured patients may pay as low as $0.


Learn More

*Please refer to study designs and additional relevant data.
†Feedback mechanisms consist of visual cues (color-controlled window and an audible “click”).
‡Subject to eligibility; restrictions apply.

REFERENCES: 1.  Tudorza® Pressair® (aclidinium bromide inhalation powder) [prescribing information]. Covis Pharma GmbH and Zug, Switzerland, August 2022 . 2. Kerwin EM, D’Urzo AD, Gelb AF, et al; on behalf of the ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).COPD.2012;9:90-101. 3. Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig.2013;33:893-904. 4. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.Eur Respir J. 2012;40:830-836. 5. Wise RA, Chapman KR, Scirica BM, et al. Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial. JAMA. 2019;321(17):1693-1701.6. Singh D, Magnussen H, Kirsten A, et al. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther. 2012;25:248-253.